Gilead's Quad Poised To Take Chunk Of Atripla's Market, If Phase III Results Hold Up
This article was originally published in The Pink Sheet Daily
Executive Summary
Solid efficacy with fewer psych effects than Atripla continue in full-length version of Phase II trials. However, hopes for superior performance have started to wane.
You may also be interested in...
Gilead Hedges Against Eventual Generic Competition For Atripla With Bristol HIV Pact
The two companies hope to repeat their Atripla success story by teaming up to develop a new combination drug for HIV containing Gilead's cobicistat and Bristol's atazanavir.
Gilead Hedges Against Eventual Generic Competition For Atripla With Bristol HIV Pact
The two companies hope to repeat their Atripla success story by teaming up to develop a new combination drug for HIV containing Gilead's cobicistat and Bristol's atazanavir.
Rilpivirine Label Highlights Risk In Patients With Higher HIV Levels, Could Limit Use
Lead investigator from Phase III trials says Edurant could be viable option in about half of treatment-naïve patients, points out safety advantages.